Xilio Therapeutics (XLO) Change in Cash (2020 - 2026)

Xilio Therapeutics has reported Change in Cash for 7 years, with the latest figure at $12.8 million in Q1 2026.

• Quarterly Change in Cash fell 62.09% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.3 million (up 13.24% YoY) and the FY2025 annual result came in at $82.3 million, up 662.98% from the prior year.
• Change in Cash declined to $12.8 million in Q1 2026 per XLO's latest filing, from $33.8 million in the prior quarter.
• Over five years, Change in Cash peaked at $40.0 million in Q2 2024 and troughed at -$27.1 million in Q1 2023.
• A 5-year average of -$2.8 million and a median of -$15.1 million in 2023 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2025: Change in Cash sank 119.08% in 2022, then surged 666.57% in 2025.
• Over 5 years, Change in Cash stood at -$18.8 million in 2022, then gained by 19.69% to -$15.1 million in 2023, then surged by 60.42% to -$6.0 million in 2024, then soared by 666.57% to $33.8 million in 2025, then tumbled by 62.08% to $12.8 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered $12.8 million, $33.8 million, and -$17.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.